Valganciclovir Production Cost Reports

The report provides a detailed analysis essential for establishing a Valganciclovir production plant. It encompasses all critical aspects necessary for Valganciclovir production, including the cost of Valganciclovir production, Valganciclovir plant cost, Valganciclovir production costs, and the overall Valganciclovir production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Valganciclovir production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Valganciclovir is an oral prodrug of Ganciclovir that works as an antiviral agent targeting cytomegalovirus (CMV). It rapidly hydrolyses into Ganciclovir, which gets phosphorylated by viral and cellular kinases into its active triphosphate form. This form competitively stops the viral DNA polymerase enzyme, combining with the growing DNA chain and causing premature termination to halt CMV replication. It is used in the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). It works both for initial induction therapy (higher doses for three weeks) followed by long-term maintenance to preserve vision. It is utilised in the prevention (prophylaxis) of CMV disease in high-risk solid organ transplant recipients, like those undergoing kidney, heart, or kidney-pancreas transplantation. It is employed in pediatric transplant patients, dosing is weight-based or by body surface area to achieve equivalent exposure, making it a cornerstone in transplant protocols.

The market for Valganciclovir is influenced by growing demand from rising solid organ and stem cell transplants around the globe. The rise in CMV infection risks in immunocompromised patients, including those with HIV and AIDS or congenital cases, boosts its demand. The presence of improved diagnostic tools for early detection and expanding use in pediatric prophylaxis makes it a popular option. The rise in population ageing, healthcare infrastructure growth, and generic competition post-patent expiry fuels its market. The industrial Valganciclovir procurement is driven by high treatment costs for extended prophylaxis courses that require payer reimbursement. Also, the availability of affordable generics from multiple manufacturers, regulatory mandates for quality and bioequivalence, supply chain reliability amid transplant surges, and clinical monitoring requirements for neutropenia and renal toxicity impact its sourcing strategies.

Raw Material for Valganciclovir Production

According to the Valganciclovir production plant project report, the key raw materials used in the production of Valganciclovir include Ganciclovir and (2S)-azido-3-methylbutyric acid.

Production Process of Valganciclovir

The extensive Valganciclovir production cost report consists of the following major industrial production process:

1. From Ganciclovir: The production process for Valganciclovir starts with Ganciclovir in DMSO treated with HOBt and triethylamine. This is followed by dropwise addition of (2S)-azido-3-methylbutyric acid in DMSO and DCC to form the bisester. This is followed by partial hydrolysis of the bisester in methanol with N, N-diisopropylethylamine and quenched with acetic acid. This is concentrated and purified by n-butanol and water partitioning, followed by methanol crystallisation, giving the monoester. The hydrogenation of monoester in methanol gives Valganciclovir hydrochloride as the final product.

Valganciclovir is an off-white to white crystalline powder serving as the oral prodrug of Ganciclovir. It has the molecular formula of C14H22N6O5·HCl and a molecular weight of 390.83 g/mol. It is structured as the L-valyl ester of Ganciclovir that has a pKa value of around 7.6. It is highly water-soluble and is formulated as film-coated tablets (450 mg) or oral powder for suspension. It is stable under standard storage but requires refrigeration for reconstituted suspensions and protection from light and moisture to prevent degradation.  On oral administration, it is hydrolysed to Ganciclovir with 60% bioavailability. It has peak plasma levels at 1-3 hours with a volume of distribution of 0.65-1.36 L/kg. It has plasma protein binding of <1-2% with a half-life of 4 hours.